Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b4ee13af463c18c765406625e1c5d44 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-18123 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-085 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
filingDate |
2017-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_676a37e1b56814cc3eedfedfa68533ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db5cc7aa31e79f17aca2c9aebf8be894 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03ed0ac640f808f34c4a48dd7bdb3f29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b72e0ea703ff83c7fa921d209fdfd01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6782d3305d4578fe56b70a4818a41d87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27e3bf013663b8a72da7abde2d703808 |
publicationDate |
2019-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2019038735-A1 |
titleOfInvention |
Vlp-based vaccines for targeting staphylococcus aureus secreted virulence factors |
abstract |
The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance. |
priorityDate |
2016-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |